ER-100 was well tolerated through Day 56 in the first 3 patients with open-angle glaucoma, with no dose-limiting toxicities, serious adverse events, or adverse events of special interest reported Two ...
Get breaking ophthalmic news, device and drug updates, clinical trial coverage, thought-leader perspective, and industry announcements.
B+L Advances Two Ophthalmic Pipeline Therapies in DED and Ocular Surface Pain ...
Merck's Remigromig Meets Primary Endpoint in Phase 2b/3 BRUNELLO Trial for DME ...
Topcon Healthcare has launched Oku Digital Health, an AI-powered company focused on using ocular data to support disease detection, referrals, and pharmaceutical research Oku combines AI-supported ...
Harrow completed its acquisition of worldwide rights to Tyrvaya, excluding Japan, for $30 million upfront and up to $70 million in sales-based milestone payments The FDA-approved nasal spray expands ...
VEO Ophthalmics will serve as the exclusive commercialization partner for VitaPixel SVS, while VitaPixel focuses on manufacturing and future R&D VitaPixel SVS adds stereoscopic 3D digital ...
Eyestem reported interim phase 2 findings for Eyecyte-RPE, an investigational RPE cell therapy for GA secondary to dry AMD, with 24 participants enrolled in the randomized controlled study Early ...
In the phase 1/2 LUCE-1 study, no serious adverse events or dose-limiting toxicities had been reported among 15 participants treated with AAVB-081, while preliminary visual function improvements were ...
SpyGlass Pharma acquired Advanced Vision Science from Santen for approximately $13 million in cash, securing commercial-scale IOL manufacturing capacity AVS currently supplies the IOL used in SpyGlass ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results